STXS · Stereotaxis, Inc.

Stereotaxis has entered into a definitive agreement to acquire Robocath, a French medical robotics company specializing in interventional cardiology and neurointerventions. The transaction represents a strategic expansion into complementary robotic technology markets, with Robocath's venture-backed innovation potentially enhancing Stereotaxis's product portfolio. The deal structure includes significant contingent payments tied to regulatory and commercial milestones, aligning consideration with future performance. The $10 million regulatory milestone depends on FDA approval of Robocath's next-generation devices, while the $15 million commercial milestone is based on achieving specified sales targets. The acquisition is conditioned on Stereotaxis completing debt restructuring and obtaining French regulatory approval, indicating potential financing and regulatory hurdles. The interim financing arrangement of approximately €1.3 million through monthly bond purchases provides Robocath with operating capital during the pre-closing period. The stock consideration cap of 19.9% of outstanding shares without shareholder approval reflects NYSE American listing requirements, potentially limiting dilution. The agreement includes customary exclusivity provisions with a termination fee mechanism designed to protect Stereotaxis from competing bids. The transaction's success depends on satisfying multiple closing conditions and achieving the earnout milestones that could increase the total consideration by 125% above the initial payment.